Virtu Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Virtu Financial’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$432K	Buy	+43,204	New	+$391K	0.01%	586
2022 Q2	–	Sell	-20,645	Closed	-$336K	–	1587
2022 Q1	$336K	Buy	+20,645	New	+$331K	0.02%	537
2021 Q3	–	Sell	-34,159	Closed	-$540K	–	1509
2021 Q2	$540K	Buy	+34,159	New	+$464K	0.05%	433
2020 Q3	–	Sell	-23,568	Closed	-$112K	–	1063
2020 Q2	$112K	Buy	+23,568	New	+$94.1K	0.01%	853
2019 Q4	$269K	Buy	77,838 +60,978	+362%	+$153K	0.03%	747
2019 Q3	$48K	Buy	+16,860	New	+$52.4K	﹤0.01%	1199
2018 Q2	–	Sell	-11,374	Closed	-$54K	–	1981
2018 Q1	$54K	Buy	+11,374	New	+$58.4K	﹤0.01%	1697

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Virtu Financial's BCRX Position: Q2 2026 in Review

Virtu Financial opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 43,204 shares worth $432K. The stake represents 0.01% of the portfolio and ranks #586 among its holdings. This is a return to the name: Virtu Financial previously reported a position in BCRX as recently as Q1 2022.

Virtu Financial first reported a position in BCRX in Q1 2018 and has held it in 7 quarters since. The position peaked at $540K in Q2 2021. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Virtu Financial held 43,204 shares of BioCryst Pharmaceuticals worth $432K as of Q2 2026.
BioCryst Pharmaceuticals was a new Virtu Financial position in Q2 2026.
BioCryst Pharmaceuticals made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #586 holding.
Virtu Financial first reported a position in BioCryst Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Virtu Financial's BioCryst Pharmaceuticals position peaked at $540K in Q2 2021.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.